These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17027583)

  • 1. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.
    Kopecky SL
    Am J Cardiol; 2006 Oct; 98(8):1115-9. PubMed ID: 17027583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of carvedilol controlled-release in cardiovascular disease.
    Fonarow GC
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients.
    Jonsson G; Abdelnoor M; Müller C; Kjeldsen SE; Os I; Westheim A
    Cardiology; 2005; 103(3):148-55. PubMed ID: 15785019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carvedilol.
    Frishman WH
    Indian Heart J; 1999; 51(3):325-32. PubMed ID: 10624077
    [No Abstract]   [Full Text] [Related]  

  • 5. Carvedilol versus metoprolol in the acute phase of myocardial infarction:
    Bonnemeier H; Ortak J; Tölg R; Witt M; Schmidt J; Wiegand UK; Bode F; Schunkert H; Richardt G
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S222-6. PubMed ID: 15683501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
    Sackner-Bernstein JD
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S25-9. PubMed ID: 14564231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients.
    Goldhammer E; Maor I; Shnitzer S; Lanir A; Abinader EG
    J Cardiovasc Med (Hagerstown); 2007 Jun; 8(6):453-6. PubMed ID: 17502762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
    McMurray J; Køber L; Robertson M; Dargie H; Colucci W; Lopez-Sendon J; Remme W; Sharpe DN; Ford I
    J Am Coll Cardiol; 2005 Feb; 45(4):525-30. PubMed ID: 15708698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity.
    Bonnemeier H; Ortak J; Tölg R; Witt M; Schmidt J; Wiegand UK; Bode F; Schunkert H; Richardt G
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S217-21. PubMed ID: 15683500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.
    Fonarow GC
    Rev Cardiovasc Med; 2006; 7(1):1-9. PubMed ID: 16534490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvedilol.
    Frishman WH
    N Engl J Med; 1998 Dec; 339(24):1759-65. PubMed ID: 9845712
    [No Abstract]   [Full Text] [Related]  

  • 14. Carvedilol: a nonselective beta blocking agent with antioxidant properties.
    Book WM
    Congest Heart Fail; 2002; 8(3):173-7, 190. PubMed ID: 12045386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
    Dargie HJ
    Lancet; 2001 May; 357(9266):1385-90. PubMed ID: 11356434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN).
    Colucci WS
    Am J Cardiol; 2004 May; 93(9A):13B-6B. PubMed ID: 15144931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial].
    Costalunga A; Gavazzi A
    Ital Heart J Suppl; 2001 Nov; 2(11):1246-7. PubMed ID: 11775420
    [No Abstract]   [Full Text] [Related]  

  • 19. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
    Ramaswamy K
    Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol: the new role of beta blockers in congestive heart failure.
    Vanderhoff BT; Ruppel HM; Amsterdam PB
    Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.